NI Health: Waiting list reimbursement scheme will see greater disparity, doctor warns
People who cannot afford to pay for medical procedures upfront are going to suffer under a new reimbursement scheme, a senior medic has said.The scheme was announced on Tuesday as part of a £215M plan outlined by Health Minister Mike Nesbitt to tackle spiralling hospital waiting lists.From next month, patients waiting longer than two years for an operation will be able to claim back money if they pay for a procedure in the Republic of Ireland.But the deputy chair of the British Medical Association in Northern Ireland, Dr Clodagh Corrigan, said that is going to make current problems worse.
"We know there is an enormous gap in health access and in poverty in Northern Ireland," she told BBC's Sunday Politics programme."If we are now in a position where we are providing a better health service to those who can afford it, we are going to see that disparity become even greater and people who cannot afford to pay for their healthcare up front really suffering."
Full details of the plan have yet to be outlined and the full range of eligible procedures covered by the cross-border scheme are not yet known.The Department of Health said patients would require prior approval before accessing the scheme.Other measures include using NI's private healthcare providers to target anyone waiting longer than four years on a hip or knee replacement, colonoscopy, hernia or gallbladder surgery.
'What are we going to lose?
Nesbitt said initially £10m will be invested in the waiting list reimbursement scheme, which will begin in June 2025.Dr Corrigan also questioned where Nesbitt will find the money that is needed."We are already in a situation in our health service where we are being propped up by staff good will, by and large," she said."They money has to be saved from somewhere so what are we going to lose and what services are we going to have to cut?"How much worse is the care that we are providing our patients on a day to day basis going to have to get to fund these savings that the minister is looking for to invest in the waiting lists?"
'Two-tier system'
Alliance MLA Nuala McAllister said Northern Ireland is now "lawing in the phase of a two-tier health system"."There has to be some equity in [the health service] if it is going to relieve the pressure elsewhere."If it is not going to relieve the pressure then we need to look again at other options."We need to use all levers and that is just the reality of it." Following the announcement, the People Before Profit MLA Gerry Carroll said the reimbursement scheme was "nothing more than stealth privatisation"."The for-profit healthcare sector has the Department over a barrel," he said in a statement."The more the Minister depends on private healthcare to solve this crisis, the weaker our NHS becomes."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
10 minutes ago
- Daily Mail
Pregnant Republican forced to evacuate Florida office after imminent death threats following her painful revelation
Florida Republican Kat Cammack shared Wednesday that her district office had to be evacuated due to death threats she received following a Wall Street Journal story published earlier this week detailed her experiences with an ectopic pregnancy last year. Cammack, 37, is currently pregnant and expecting her first child in mid-August. In a post on X, formerly Twitter, the congresswoman spoke of 'imminent death threats against me, my unborn child, my family and my staff' based on her revealing her story about a 'nonviable pregnancy with no heartbeat.' 'Since then, we've received thousands of hate-filled messages and dozens of credible threats from pro-abortion activists, which law enforcement is actively investigating,' she added, noting the uptick of violent threats against elected officials. In a statement sent to the Daily Mail by Cammack's office she also noted: 'This is the unacceptable reality we're facing: sharing a personal health story in an effort to improve healthcare for women and their children can lead to threats, harassment, and evacuation orders'. 'This should be a wake-up call. Women deserve better. And so does the national healthcare dialogue, Cammack added. The threats come just over a week after a Minnesota lawmaker and her husband were assassinated at their home by a gunman. Cammack also clarified that she did not vote for Florida's heartbeat law since she serves as a U.S. congresswoman, not a state legislature. Florida's heartbeat law, passed in 2023, bans abortion once a fetal heartbeat can be detected — typically around six weeks of pregnancy. 'Let me be clear: I will not be intimidated. I won't back down in the fight for women and families. Ensuring women have the resources and care they deserve is critical. We need real conversations about maternal healthcare in America—conversations based on truth, not fear,' Cammack said. Today, we had to evacuate our offices due to imminent death threats against me, my unborn child, my family, and my staff. These threats erupted after the Wall Street Journal reported on my life-threatening ectopic pregnancy—a nonviable pregnancy with no heartbeat. Since then,… — Rep. Cammack Press Office (@RepKatCammack) June 26, 2025 The Wall Street Journal reported that Cammack was about five weeks pregnant when she required a methotrexate injection to treat an ectopic pregnancy — a condition in which the embryo cannot survive. Cammack is a co-chair of the House Pro-Life Caucus, and opposes abortion, but backs exemptions in the case of rape, incest and when the life of the mother is in danger. Cammack's team said some of the threats came in as comments on a series of photos she and her husband Matt Harrison took to celebrate her pregnancy.
Times
14 minutes ago
- Times
Test could identify women at increased risk of miscarriage
British scientists have developed a test that detects abnormalities in the womb lining, which could help identify women with an increased risk of suffering a miscarriage. It is hoped it will pave the way for more treatments to prevent repeated pregnancy losses. About one in six pregnancies are lost and the majority of these happen before 12 weeks. Each miscarriage increases the risk of another occurring. Charities said that the findings could help to provide an explanation for repeated miscarriages. According to the team from Warwick University, in some women the womb lining does not react as it should during pregnancy. The test they developed can measure signs of a healthy or defective reaction in the womb lining. It is now being piloted to help more than a thousand patients at Tommy's National Centre for Miscarriage Research at University Hospital Coventry & Warwickshire (UHCW).Dr Jo Muter, the lead author of the study and a researcher at Warwick Medical School, told the BBC: 'Many women are told they've just had 'bad luck', but our findings show that the womb itself may be setting the stage for pregnancy loss, even before conception takes place.'Much of the research in this area has focused on the embryo, rather than the womb hosting it. The womb lining during pregnancy undergoes a reaction, which converts the cells to a more supportive state. In cases where this does not happen or this reaction is faulty, the risk of bleeding and pregnancy loss increases. When a faulty reaction occurs, it is more likely to occur again, according to the research team. Dr Jyotsna Vohra, director of research at Tommy's, said that care and treatment for those who experienced pregnancy or baby loss varied unacceptably across the UK. 'There should be no barriers to accessing any test or treatment that has been proven to make a difference. 'We hope NHS decision-makers will look carefully at the results of the Coventry pilot project and consider rolling this test out nationwide, so that everyone who might benefit has that opportunity.' Vohra said that women suffering trauma after recurrent miscarriages were often 'left without answers', and that the test could offer some consolation by explaining the cause. The Warwick team analysed around 1,500 biopsies from more than 1,300 women for the study. Abnormal responses in the menstrual lining recurred across menstrual cycles for some women, suggesting a consistent cause of miscarriage risk which could be prevented. One of the women offered the new test, Holly Milkouris, said that it was 'life-changing' after she suffered five miscarriages. After the problems affecting her womb lining were detected and treated, Milkouris and her husband had two healthy children, now aged three and 17 months. Milkouris told The Guardian: 'We felt lost and were beginning to accept that I might never successfully carry a pregnancy. 'The treatments that typically can help women who have experienced miscarriages hadn't worked for us and each time we tried again we felt like we were rolling a dice with the baby's life. 'For the first time the results of my biopsy were normal, and we went on to have not one, but two successful pregnancies.'Muter said that the next step would be to use the test to assess potential drug treatments. Sitagliptin, a drug usually used to treat diabetes, is currently the go-to option for problems with the womb lining but Muter said that other existing drugs could be repurposed. Only 20 per cent of potential drugs are currently tested on pregnant women.
Telegraph
17 minutes ago
- Telegraph
Weight-loss jabs linked to pancreas problems after 10 deaths
Weight-loss jabs have been linked to pancreas problems after 10 patients died. Hundreds of people have reported problems with their pancreas linked to taking weight-loss and diabetes jabs including Mounjaro, Wegovy and Ozempic, prompting health officials to launch a new study into side effects. Ten cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have been fatal. Since the GLP-1 medicines were licensed, there have been hundreds of cases of acute and chronic pancreatitis, according to data from the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA). These cases are not confirmed as having been caused by the medicines, but the person who reported them suspected they might be. They include 181 reported cases of acute and chronic pancreatitis linked to tirzepatide - the active ingredient for Mounjaro - and five of those people died. Some 116 reported reactions of this kind were linked to liraglutide, one of which was fatal, while there were 113 cases of acute and chronic pancreatitis linked to semaglutide - the active ingredient for Ozempic and Wegovy - where one person died, and 101 reported reactions of this kind were linked to exenatide, from which three people died. Then there were 52 reported reactions linked to dulaglutide and 11 reported reactions linked to lixisenatide, but no fatalities were linked to either drug. Pancreatitis is the inflammation of the pancreas, a gland located behind the stomach that aids in digestion and blood sugar regulation. In severe cases it can lead to organ failure. Nonetheless, the Yellow Card Biobank project, launched by the MHRA and Genomics England, will see researchers examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by genetic makeup. The MHRA is calling for those who are taking GLP-1 medicine, who have been admitted to hospital due to acute pancreatitis, to submit a report to its Yellow Card scheme. When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study. Patients will be asked to submit more information and a saliva sample, which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes. GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss. Recent estimates suggest that about 1.5 million people in the UK are taking weight-loss jabs. Health officials have suggested they can help turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects. Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea. And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients. Dr Alison Cave, the MHRA's chief safety officer, said: 'Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone.' She added: 'Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions - enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. 'To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. 'Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.' Professor Matt Brown, chief scientific officer of Genomics England, said: ' GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. 'We believe there is real potential to minimise these with many adverse reactions having a genetic cause. 'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'
